Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FT 011

Next Previous
Drug Profile

FT 011

Alternative Names: FT-011; SHP 627

Latest Information Update: 26 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fibrotech Therapeutics; University of Melbourne
  • Developer Certa Therapeutics; OccuRx; Shire
  • Class Alkynes; Anthranilic acids; Antifibrotics; Antiglaucomas; Caffeic acids; Heart failure therapies; Skin disorder therapies; Small molecules; Urologics
  • Mechanism of Action GPR68 protein antagonists; Platelet-derived growth factor inhibitors; TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Focal segmental glomerulosclerosis; Systemic scleroderma
  • Phase I Renal failure
  • Discontinued Diabetic nephropathies; Glaucoma; Heart failure; Kidney disorders

Most Recent Events

  • 19 Feb 2024 FT 011 receives Fast track status from the US FDA for Systemic scleroderma
  • 23 Nov 2023 Discontinued - Phase-I for Glaucoma in Australia (PO) (Certa Therapeutics pipeline, November 2023)
  • 23 Nov 2023 Discontinued - Phase-II for Diabetic nephropathies in Australia (PO) (Certa Therapeutics pipeline, November 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top